Dermatology Times profiles new Castle Biosciences Melanoma test

Gene expression profiling with a commercially available test (DecisionDx-Melanoma, Castle Biosciences) provides useful prognostic information for patients with high-risk cutaneous melanoma who undergo sentinel lymph node (SLN) biopsy, and particularly for those found to be node-negative, according to a study presented at the annual meeting of the American Society for Clinical Oncology.

Read More

Read More
Castle Biosciences Announces $11.8M Financing

Castle Biosciences, Inc., a cancer-focused molecular diagnostics company, today announced the completion of an $11.8 million financing. The round was led by new investor HealthQuest Capital, with participation by Castle Biosciences’ current investors including Mountain Group Capital and Affiliates, Longfellow Venture Partners and others. In conjunction with this financing, Garheng Kong, M.D., Ph.D., Managing Partner of HealthQuest Capital, will join Castle Biosciences’ Board of Directors.

Read More

Read More
FAST Launches Upset Stomach Relief

First Aid Shot Therapy, makers of First Aid Shot Therapy Pain Relief, today announced the launch of its newest offering, First Aid Shot Therapy Upset Stomach. Upset Stomach is the second variant to be launched in the F.A.S.T. range of products and it is formulated to relive upset stomach symptoms. It comes in a great-tasting, smooth, ready-to-drink, liquid shot form, which starts to work immediately.

Read More

Read More
First Aid Shot Therapy Introduces Upset Stomach Relief

First Aid Shot Therapy, makers of First Aid Shot Therapy Pain Relief, today announced the launch of its newest offering, First Aid Shot Therapy Upset Stomach. Upset Stomach is the second variant to be launched in the F.A.S.T. range of products and it is formulated to relive upset stomach symptoms. It comes in a great-tasting, smooth, ready-to-drink, liquid shot form, which starts to work immediately.

Read More

Read More
Vestagen Obtains Worldwide Rights to Schoeller Technologies Underlying Key Properties of its Vestex® Protective Healthcare Uniforms

Vestagen Technical Textiles, Inc., today announced that it has obtained worldwide rights from Schoeller Technologies AG to certain technologies that are integral to the unique properties of Vestex, the first of its families of active barrier protective fabrics that are clinically proven to prevent or reduce the acquisition and retention of microbes and other contaminants.

Read More

Read More